Last reviewed · How we verify
Half-Dose Depot Triptorelin
Half-dose depot triptorelin is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production.
Half-dose depot triptorelin is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production. Used for Advanced prostate cancer, Hormone-responsive breast cancer, Endometriosis.
At a glance
| Generic name | Half-Dose Depot Triptorelin |
|---|---|
| Sponsor | Tehran University of Medical Sciences |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology; Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Triptorelin is a synthetic GnRH agonist that initially stimulates the pituitary gland but with continuous exposure causes downregulation of GnRH receptors, resulting in sustained suppression of gonadal hormone secretion. The half-dose depot formulation provides prolonged hormone suppression with a reduced drug load compared to standard-dose formulations, potentially improving tolerability while maintaining therapeutic efficacy.
Approved indications
- Advanced prostate cancer
- Hormone-responsive breast cancer
- Endometriosis
- Uterine fibroids
Common side effects
- Hot flashes
- Decreased libido
- Erectile dysfunction
- Injection site reactions
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |